[Consequences of cholesterol reduction in cardiovascular diseases. What costs should be allowed to prolong life a year?].
De Faire
U
U
Kliniken för akut- och kardiovaskulär medicin, Karolinska sjukhuset, Karolinska institutet, Stockholm.
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics*; D002318:Cardiovascular Diseases / Q000097:blood / Q000150:complications / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000191:economics* / Q000209:etiology / Q000517:prevention & control; D013548:Sweden; D026712:Value of Life
D000924:Anticholesteremic Agents